01—Abstract
Summary
Summary of the 10-K filed December 20, 2002. Cited figures are marked; the original filing is the authoritative source.
Agilent Technologies, Inc.'s 2002 10-K filing reveals a challenging year marked by a significant revenue decline and a substantial net loss.
The company experienced a 28% drop in net revenue to $6.01 billiona, primarily driven by weakness in the telecommunications, semiconductor, and electronics industries, which led to a net loss of $1.03 billion. This performance is largely attributed to a prolonged economic downturn that began in 2001. In response to these conditions, Agilent implemented significant restructuring efforts, including workforce reductions totaling approximately 8,000 employees, and plans for further cost reductions.
The company's strategic focus remains on its three core businesses: test and measurement, semiconductor products, and life sciences and chemical analysis, with an emphasis on developing new products and technologies to drive future growth. Despite the headwinds, Agilent maintains a strong balance sheet with significant cash and cash equivalents, positioning it to navigate the current economic climate and invest in its long-term strategic priorities.
02—Key points
Key Highlights
- Agilent Technologies experienced a significant revenue decline of 28% in fiscal year 2002, reaching $6.01 billion, down from $8.40 billion in fiscal year 2001.
- The company reported a substantial net loss of $1.03 billion for fiscal year 2002, a sharp reversal from a net profit of $174 million in fiscal year 2001.
- The Test and Measurement segment saw the most significant revenue drop, down 39% year-over-year, reflecting weakness in telecommunications and electronics markets.
- Agilent implemented significant restructuring plans, including workforce reductions of approximately 8,000 employees and associated charges of $474 million in 2002, aimed at reducing costs and returning to profitability.
- The company's cash and cash equivalents remained strong at $1.84 billion as of October 31, 2002.
- Agilent completed the sale of its healthcare solutions business in August 2001, which contributed a significant gain to fiscal year 2001 results but also resulted in a loss on adjustments in fiscal year 2002.
- The company continues to invest in Research and Development, spending $1.17 billion in fiscal year 2002, despite the challenging economic environment.
03—Questions
Frequently Asked Questions
What were the primary drivers of Agilent's financial performance in fiscal year 2002?
Agilent's financial performance in fiscal year 2002 was primarily driven by a significant economic downturn affecting its key markets, particularly telecommunications, semiconductor, and electronics. This led to a substantial decline in revenue and a net loss. The company's restructuring efforts, while aimed at cost reduction, also contributed to financial charges during the year.
How did the company's different business segments perform?
The Test and Measurement segment experienced the most significant decline in revenue and operations due to industry weakness. The Semiconductor Products segment also saw a revenue decrease, though orders showed some improvement. The Life Sciences and Chemical Analysis segment demonstrated more resilience, with modest revenue growth and positive earnings from operations.
What restructuring actions did Agilent undertake, and what was their financial impact?
Agilent undertook significant restructuring efforts, including workforce reductions of approximately 8,000 employees and facility consolidations. These actions resulted in total restructuring and asset impairment charges of $474 million in fiscal year 2002. The company aimed to reduce costs and improve profitability through these measures.
What is Agilent's outlook for the upcoming year, and what are its key strategies?
Agilent's outlook for the upcoming year (2003) was cautious, with expectations of continued weakness in some markets like wireline telecommunications, but with potential for growth in others, driven by new products. The company's strategy involved continued cost management, focus on new product introductions to drive revenue growth, and leveraging its strong balance sheet to navigate the economic challenges.
04—Continue